Hospitalization Rates Are Highest in the First 5 Years of Systemic Sclerosis: Results From a Population-based Cohort (1980–2016)

REFERENCES

1. 1.↵
   1. Denton CP,
   2. Khanna D.

   Systemic sclerosis. Lancet 2017; 390:1685-99.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Rubio-Rivas M,
   2. Royo C,
   3. Simeon CP,
   4. Corbella X,
   5. Fonollosa V.

   Mortality and survival in systemic sclerosis: systematic review and meta-analysis. Semin Arthritis Rheum 2014;44:208-19.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Tyndall AJ,
   2. Bannert B,
   3. Vonk M,
   4. Airo P,
   5. Cozzi F,
   6. Carreira PE, et al.

   Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010;69:1809-15.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Fischer A,
   2. Zimovetz E,
   3. Ling C,
   4. Esser D,
   5. Schoof N.

   Humanistic and cost burden of systemic sclerosis: a review of the literature. Autoimmun Rev 2017;16:1147-54.

   OpenUrl
5. 5.↵
   1. Furst DE,
   2. Fernandes AW,
   3. Iorga SR,
   4. Greth W,
   5. Bancroft T.

   Annual medical costs and healthcare resource use in patients with systemic sclerosis in an insured population. J Rheumatol 2012;39:2303-9.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Neitert PJ,
   2. Silverstein MD,
   3. Silver RM.

   Hospital admissions, length of stay, charges, and in-hospital death among patients with systemic sclerosis. J Rheumatol 2001;28:2031-7.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Chung L,
   2. Krishnan E,
   3. Chakravarty EF.

   Hospitalizations and mortality in systemic sclerosis: results from the Nationwide Inpatient Sample. Rheumatology 2007;46:1808-13.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Poudel DR,
   2. George M,
   3. Dhital R,
   4. Karmacharya P,
   5. Sandorfi N,
   6. Derk DT.

   Mortality, length of stay, and cost of hospitalization among patients with systemic sclerosis: results from the National Inpatient Sample. Rheumatology 2018;57:1611-22.

   OpenUrl
9. 9.↵
   1. Morrisroe K,
   2. Stevens W,
   3. Sahhar J,
   4. Ngian JS,
   5. Ferdowski N,
   6. Hansen D, et al.

   The clinical and economic burden of systemic sclerosis related interstitial lung disease. Rheumatology 2020;59:1878-88.

   OpenUrl
10. 10.↵
    1. Rocca WA,
    2. Yawn BP,
    3. St Sauver JL,
    4. Grossardt BR,
    5. Melton LJ.

    History of the Rochester Epidemiology Project: half a century of medical records linkage in a US population. Mayo Clin Proc 2012;87:1202-13.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Charlson ME,
    2. Pompei P,
    3. Ales KL,
    4. MacKenzie CR.

    A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Agency for Healthcare Research and Quality

    . Healthcare Cost and Utilization Project (HCUP). [Internet. Accessed February 10, 2021.] Available from: www.hcup-us.ahrq.gov/home.jsp
13. 13.↵
    1. Michet CJ III,
    2. Achenbach SJ,
    3. Crowson CS,
    4. Matteson EL.

    Hospitalization rates and utilization among patients with giant cell arteritis: a population-based study from 1987 to 2012. Semin Arthritis Rheum 2015;45:70-4.

    OpenUrl
14. 14.↵
    1. Ungprasert P,
    2. Crowson CS,
    3. Achenbach SJ,
    4. Carmona EM,
    5. Matteson EL.

    Hospitalization among patients with sarcoidosis: a population-based cohort study 1987-2015. Lung 2017;195:411-8.

    OpenUrl
15. 15.↵
    1. Peoples C,
    2. Medsger TA Jr,
    3. Rosario BL,
    4. Feghali-Bostwick CA.

    Gender differences in systemic sclerosis: relationship to clinical features, serologic status and outcomes. J Scleroderma Relat Disord 2016;1:177-240.

    OpenUrl